Narlaprevir

J05AP14(WHO) RU: Rx-only (1R,2S,5S)-3-[(2S)-2-[ [1-(tert-Butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide 865466-24-6 11857239 DB14760Y ID10031710 2857LA2O07 D09644 CHEBI:173104 ChEMBL1255891 DTXSID801025746 CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC3(CS(=O)(=O)C(C)(C)C)CCCCC3)C(C)(C)C)C2(C)C)C(=O)C(=O)NC4CC4 InChI=1S/C36H61N5O7S/c1-10-11-15-24(27(42)30(44)37-22-16-17-22)38-29(43)26-25-23(35(25,8)9)20-41(26)31(45)28(33(2,3)4)39-32(46)40-36(18-13-12-14-19-36)21-49(47,48)34(5,6)7/h22-26,28H,10-21H2,1-9H3,(H,37,44)(H,38,43)(H2,39,40,46)/t23-,24-,25-,26-,28+/m0/s1Key:RICZEKWVNZFTNZ-LFGITCQGSA-N Narlaprevir(trade nameArlansa,codenamed SCH 900518),is aninhibitorofNS3/4Aserine protease, intended for the treatment of chronichepatitis Ccaused by genotype 1 virus in combination with otherantiviral drugs. Narlaprevir is the first Russian tableted medication for the treatment of chronic hepatitis C.